SynthesisEndocrinology, diabetes & metabolism2026
Efficacy of Telmisartan in MASLD/NAFLD: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Synthesis in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundActivation of the renin-angiotensin-aldosterone system contributes to hepatic inflammation in metabolic dysfunction-associated steatotic liver disease (MASLD). Telmisartan, an angiotensin II receptor blocker with partial PPAR-γ agonistic activity, has been hypothesized to confer metabolic benefits; however, current clinical evidence has not consistently demonstrated such effects.
aimThis systematic review and meta-analysis evaluated the efficacy of telmisartan on metabolic, biochemical, and histological outcomes in MASLD.
methodsElectronic databases (PubMed, Embase, Web of Science, Scopus) were searched through 2026 for randomized controlled trials (RCTs) investigating telmisartan in adults with MASLD. Risk of bias was assessed using the RoB2 tool. Random-effects meta-analyses calculated pooled mean differences (MDs) with 95% confidence intervals (CIs).
resultsSix RCTs comprising 258 participants (126 telmisartan, 132 controls) met the inclusion criteria. Telmisartan treatment was associated with a modest reduction in fasting blood sugar compared with controls (MD = -2.78 mg/dL; 95% CI -5.17 to -0.39; p = 0.023); however, this finding was accompanied by substantial heterogeneity (I
conclusionCurrent evidence does not demonstrate consistent metabolic, biochemical, or histological benefits of telmisartan in MASLD. Although a modest reduction in fasting blood glucose was observed, substantial between-study heterogeneity and the modest effect size limit confidence in this finding.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.